Lisata Therapeutics
LSTA
23 hedge funds and large institutions have $2.08M invested in Lisata Therapeutics in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% more ownership
Funds ownership: 0.53% → 0.53% (+0%)
2% less capital invested
Capital invested by funds: $2.13M → $2.08M (-$44K)
8% less funds holding
Funds holding: 25 → 23 (-2)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $5K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$49K |
| 2 |
Renaissance Technologies
New York
|
+$46.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.93K |
| 4 |
Morgan Stanley
New York
|
+$467 |
| 5 |
BlackRock
New York
|
+$323 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$49.4K |
| 2 |
STA
Summit Trail Advisors
New York
|
-$46K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$4K |
| 4 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
-$3K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$755 |
LSTA Hedge Fund Activity: Q4 2019 in Review
23 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q4 2019, worth a combined $2.08M — down 2.1% from $2.13M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LSTA and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 4 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $49K. The largest seller was Deutsche Bank, cutting an estimated $49.4K.
- 23 institutional investors held Lisata Therapeutics (LSTA) as of Q4 2019, down from 25 in Q3 2019.
- Funds reported $2.08M of Lisata Therapeutics stock for Q4 2019, down 2.1% quarter-over-quarter.
- 2 funds opened new Lisata Therapeutics positions in Q4 2019 and 3 closed out, a net change of -1 holder.
- The largest Lisata Therapeutics buyer in Q4 2019 was Susquehanna International Group, an estimated $49K added.
- The largest Lisata Therapeutics seller in Q4 2019 was Deutsche Bank, an estimated $49.4K sold.
Based on aggregated 13F filings for Q4 2019.